Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'
RHONE GLACIER, Switzerland (AP) — Drip, drip. Trickle, trickle.
That's the sound of water seeping from a sunbaked and slushy Swiss glacier that geoscientists are monitoring for signs of continued retreat by the majestic masses of ice under the heat of global warming.
In recent years, glaciologists like Matthias Huss of the Federal Institute of Technology in Zurich, known as ETHZ, and others have turned to dramatic measures to help protect glaciers like the Rhone Glacier, which feeds into the river of the same name that runs through Switzerland and France.
One of those desperate steps involves using giant sheets to cover the ice like blankets to slow the melt.
Switzerland is continental Europe's glacier capital, with some 1,400 that provide drinking water, irrigation for farmland in many parts of Europe including French wine country, and hydropower that generates most of the country's electricity.
The number has been dwindling. The Alpine country has already lost up to 1,000 small glaciers, and the bigger ones are increasingly at risk.
Drilling into glaciers to track what's happening inside
Huss hosted The Associated Press for a visit to the sprawling glacier this month, as he carried out his first monitoring mission as summer temperatures accelerate the thaw. Under normal conditions, glaciers can regenerate in the winter, but climate change is threatening that.
'I always say glaciers are the ambassadors of climate change because they can spread this message in a very understandable way,' Huss said. 'They also cause good feelings because glaciers are beautiful. We know them from our holidays.'
The vast expanse of blue, gray and white ice is riddled with cracks and grooves, and Huss says his teams at the Swiss GLAMOS glacier monitoring group have spotted a new phenomenon in Switzerland: holes appearing beneath the surface that at times widen so much that the ice above collapses.
Huss uses an auger to bore into the ice, sending frosty chips upward as if from a gushing fountain. It's part of a process that involves using stakes and poles to track ice loss from melting.
A better understanding of glacier melt
Huss monitors melting not just at the top but also from the base of glaciers.
'Normally glaciers melt from the top because of the warm air, because of their radiation from the sun. But in recent years we realized at several sites that there is a substantive melt from the bottom,' Huss said. 'If there are some channels in the ice through which air is circulating, this can excavate big holes under the ice.'
The Alps were covered with ice 20,000 years ago, but no more. It's the same story elsewhere. Experts have warned that some two-thirds of the world's glaciers are set to disappear by the end of this century
Huss says only humans can help save them.
'It's difficult to save this very glacier because it could only be saved — or at least made to retreat slower — by bringing down CO2 emissions,' he said. 'But everybody can contribute on their own to reduce CO2 emissions as far as possible.'
'This will not help this glacier immediately, but it will help all glaciers in the long range,' he added. 'This is the important thing that we should think of if we see this melting ice and this big retreat — that it's time to act now.'
A glacier gives way, and a village is destroyed
The concerns about Switzerland's glaciers intensified recently after the southwestern village of Blatten, tucked near the Birch Glacier, was largely destroyed by a slide of rock and glacier ice in May. The village had been evacuated ahead of the slide, which covered dozens of homes and buildings and left just a few rooftops visible.
A review of data showed that the Birch Glacier was a rarity in that it has been advancing while most glaciers have been receding. And its advance had been increasing in recent years, to the point that it was flowing at about 10 meters (about 30 feet) per day shortly before the collapse — a rate Huss called 'completely unsustainable.'
Huss said the landslide was triggered by rocks piling onto the glacier, though he also called Birch's advance a 'precursor.'
The main takeaway from the Birch Glacier collapse, Huss says, is that 'unexpected things happen.'
'If you ask me, like three weeks ago, nobody would have guessed that the whole village is going to be destroyed,' he said. 'I think this is the main lesson to be learned, that we need to be prepared.'
___
AP journalist Jamey Keaten in Geneva contributed to this report.
___
The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Photos show Swiss glaciers' uncertain future as 'ambassadors of climate change'
RHONE GLACIER, Switzerland (AP) — Drip, drip. Trickle, trickle. That's the sound of water seeping from a sunbaked and slushy Swiss glacier that geoscientists are monitoring for signs of continued retreat by the majestic masses of ice under the heat of global warming. In recent years, glaciologists like Matthias Huss of the Federal Institute of Technology in Zurich, known as ETHZ, and others have turned to dramatic measures to help protect glaciers like the Rhone Glacier, which feeds into the river of the same name that runs through Switzerland and France. One of those desperate steps involves using giant sheets to cover the ice like blankets to slow the melt. Switzerland is continental Europe's glacier capital, with some 1,400 that provide drinking water, irrigation for farmland in many parts of Europe including French wine country, and hydropower that generates most of the country's electricity. The number has been dwindling. The Alpine country has already lost up to 1,000 small glaciers, and the bigger ones are increasingly at risk. Drilling into glaciers to track what's happening inside Huss hosted The Associated Press for a visit to the sprawling glacier this month, as he carried out his first monitoring mission as summer temperatures accelerate the thaw. Under normal conditions, glaciers can regenerate in the winter, but climate change is threatening that. 'I always say glaciers are the ambassadors of climate change because they can spread this message in a very understandable way," Huss said. "They also cause good feelings because glaciers are beautiful. We know them from our holidays.' The vast expanse of blue, gray and white ice is riddled with cracks and grooves, and Huss says his teams at the Swiss GLAMOS glacier monitoring group have spotted a new phenomenon in Switzerland: holes appearing beneath the surface that at times widen so much that the ice above collapses. Huss uses an auger to bore into the ice, sending frosty chips upward as if from a gushing fountain. It's part of a process that involves using stakes and poles to track ice loss from melting. A better understanding of glacier melt Huss monitors melting not just at the top but also from the base of glaciers. 'Normally glaciers melt from the top because of the warm air, because of their radiation from the sun. But in recent years we realized at several sites that there is a substantive melt from the bottom,' Huss said. 'If there are some channels in the ice through which air is circulating, this can excavate big holes under the ice.' The Alps were covered with ice 20,000 years ago, but no more. It's the same story elsewhere. Experts have warned that some two-thirds of the world's glaciers are set to disappear by the end of this century Huss says only humans can help save them. 'It's difficult to save this very glacier because it could only be saved — or at least made to retreat slower — by bringing down CO2 emissions," he said. 'But everybody can contribute on their own to reduce CO2 emissions as far as possible." 'This will not help this glacier immediately, but it will help all glaciers in the long range,' he added. "This is the important thing that we should think of if we see this melting ice and this big retreat — that it's time to act now.' A glacier gives way, and a village is destroyed The concerns about Switzerland's glaciers intensified recently after the southwestern village of Blatten, tucked near the Birch Glacier, was largely destroyed by a slide of rock and glacier ice in May . The village had been evacuated ahead of the slide, which covered dozens of homes and buildings and left just a few rooftops visible. A review of data showed that the Birch Glacier was a rarity in that it has been advancing while most glaciers have been receding. And its advance had been increasing in recent years, to the point that it was flowing at about 10 meters (about 30 feet) per day shortly before the collapse — a rate Huss called 'completely unsustainable.' Huss said the landslide was triggered by rocks piling onto the glacier, though he also called Birch's advance a 'precursor." The main takeaway from the Birch Glacier collapse, Huss says, is that 'unexpected things happen.' 'If you ask me, like three weeks ago, nobody would have guessed that the whole village is going to be destroyed,' he said. "I think this is the main lesson to be learned, that we need to be prepared.' ___ AP journalist Jamey Keaten in Geneva contributed to this report. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at .


Associated Press
2 hours ago
- Associated Press
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Jun 25, 2025-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4 'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.' BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. 'Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.' PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. 'It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.' DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: . References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol . 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol . 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch . 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio ® U.S. Prescribing Information. Available online . Accessed June 2025 6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR . 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online . Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed June 2025 View source version on CONTACT: For further information: Christian Marcoux, Chief Communications Officer [email protected] +41 76 315 26 50 Richard Harbinson Corporate Communications Director [email protected] +41 76 210 60 62 Céline Buguet Franchises and R&D Communications Director [email protected] +41 76 249 90 87 Emil Ivanov Head of Strategy, Investor Relations, and ESG [email protected] +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director [email protected] +41 21 642 76 43 KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Galderma Copyright Business Wire 2025. PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM
Yahoo
3 hours ago
- Yahoo
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4 Enrollment for Galderma's phase II studies of nemolizumab is planned to begin in H2 2025 ZUG, Switzerland, June 25, 2025--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc.1,3,4 "Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions."BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs.1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age.2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments.1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. "Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition."PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly.3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood.3,7 There are currently no approved treatments for this condition.3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. "It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin."DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch. 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio® U.S. Prescribing Information. Available online. Accessed June 2025 6. Nemluvio® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR. 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online. Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed June 2025 View source version on Contacts For further information:Christian Marcoux, Communications +41 76 315 26 50Richard HarbinsonCorporate Communications +41 76 210 60 62Céline BuguetFranchises and R&D Communications +41 76 249 90 87Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12Jessica CohenInvestor Relations and Strategy +41 21 642 76 43 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data